Correlation of Cystatin-c with Albumin Creatinine Ratio for the Diagnosis of Diabetic Nephropathy in Patients with Type 2 Diabetes: A Cross-sectional Study in Medan Indonesia

Rina Amelia; Dina Keumala Sari; Riri Andri Muzasti; Hendri Wijaya

doi:10.3889/oamjms.2022.9249

Authors

Rina Amelia Department of Community Medicine and Public Health, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia https://orcid.org/0000-0002-0419-9622
Dina Keumala Sari Department of Nutrition, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
Riri Andri Muzasti Department of Internal Medicine, Division of Nephrology and Hypertension, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
Hendri Wijaya Department of Pediatrics, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia; H. Adam Malik General Hospital, Medan, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2022.9249

Keywords:

Cystatin-c, Albumin creatinine ratio, Nephropathy complications, Type 2 DM

Abstract

BACKGROUND: Diabetic nephropathy (ND) is one of the main complications of chronic microvascular diabetes mellitus (DM) and the leading cause of the end-stage renal disease (ESRD), accounting for nearly half of all ND cases with ESRD incidence in developed countries. Recently, cystatin C serum has been considered as a new biomarker for the diagnosis of kidney damage. Cystatin-C is an appropriate marker for GFR measurement because it is not affected by age, weight, gender, and protein intake. Early detection of abnormal renal function is essential to slow progression to a further stage of nephropathy or the final stage of kidney disease.

AIM: The aim of the study was to analyze the correlation between cystatin-C and ACR to early detection of nephropathy complications.

MATERIALS AND METHODS: This study uses an observational analytical research design with a cross-sectional approach. The research was conducted on patients with type 2 diabetes mellitus (T2DM) who were visiting the primary health service in Medan that met the inclusion and exclusion criteria. The sample count was 89 respondents. The sampling method is done through consecutive sampling. The source of this research data is primary data, including the results of cystatin-c examination and albumin. Data analysis used Spearman correlation using SPSS for Windows software.

RESULTS: There was a significant relationship between cystatin-C levels and albuminuria (p<0.05).

CONCLUSION: Diabetic nephropathy is a clinical syndrome characterized by persistent albuminuria and progressive decline of renal function, cystatin-C and albuminuria levels can be used as early detection of nephropathy complications.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Zhou B, Zou H, Xu G. Clinical utility of serum cystatin c in predicting diabetic nephropathy among patients with diabetes mellitus: A meta-analysis. Kidney Blood Pressure Res. 2016;41(6):919-28. https://doi.org/10.1159/000452593 PMid:27889768 DOI: https://doi.org/10.1159/000452593

Alsailawi HA, Mudhafar M, Majhool AA, Asaad A. Study of cystatin c as early biomarker of nephropathy in patients with Type 2 DM and risk stratification in Tarnaka hospital of Hyderabad City in India. J US China Med Sci. 2019;16:232-41. https://doi.org/10.17265/1548-6648/2019.05.004 DOI: https://doi.org/10.17265/1548-6648/2019.05.004

Sapkota S, Khatiwada S, Shrestha S, Baral N, Maskey R, Majhi S, et al. Diagnostic accuracy of serum cystatin c for early recognition of nephropathy in Type 2 diabetes mellitus. Int J Nephrol. 2021;26:8884126. https://doi.org/10.1155/2021/8884126 DOI: https://doi.org/10.1155/2021/8884126

Zaman A, Rahim A, Malik A. Correlation of cystatin C with glomerular filtration rate and urine albumin an early prediction of kidney status in Type 2 diabetes mellitus. Isra Med J. 2019;11(5):359-62.

Elsayed MS, El Badawy A, Omar R, Mohamed A. Serum cystatin C as an indicator for early detection of diabetic nephropathy in Type 2 diabetes mellitus. Diabetes Metab Syndr. 2019;13(1):374-81. https://doi.org/10.1016/j.dsx.2018.08.017 PMid:30641728 DOI: https://doi.org/10.1016/j.dsx.2018.08.017

Amelia R, Harahap J, Yunanda Y, Wijaya H, Fujiati II, Yamamoto Z. Early detection of macrovascular complications in Type 2 diabetes mellitus in Medan, North Sumatera, Indonesia: A cross-sectional. F1000Res. 2021;10:808. https://doi.org/10.12688/f1000research.54649.1 PMid:34527220 DOI: https://doi.org/10.12688/f1000research.54649.1

Amelia R, Sari MD, Virgayanti V, Ariga RA Harahap MS. Effect of duration of illness and lipid profile of type 2 Diabetes Mellitus patients on diabetic retinopathy. IOP Conf Ser Earth Environ Sci. 2021;713(1):012058. https://doi.org/10.1088/1755-1315/713/1/012058 DOI: https://doi.org/10.1088/1755-1315/713/1/012058

Amelia R, Sari D, Muzasti R, Fujiati II, Wijaya H. Early detection of diabetic nephropathy based on albumin creatinine ratio (ACR) in Type 2 diabetes mellitus patients in Medan Indonesia. Fam Med Prim Care Rev. 2021;23(2):135-8. https://doi.org/10.5114/fmpcr.2021.105903 DOI: https://doi.org/10.5114/fmpcr.2021.105903

Selby NM, Taal MW. An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab. 2020;22:3-15. https://doi.org/10.1111/dom.14007 PMid:32267079 DOI: https://doi.org/10.1111/dom.14007

Evans K, Pyart R, Steenkamp R, Whitlock T, Stannard C, Gair R, et al. UK renal registry 20th annual report: Introduction. Nephron. 2018;139(1):1-12. https://doi.org/10.1159/000490958 PMid:29990996 DOI: https://doi.org/10.1159/000490958

Koye DN, Shaw JE, Reid CM, Atkins RC, Reutens AT, Magliano DJ. Incidence of chronic kidney disease among people with diabetes: A systematic review of observational studies. Diabetic Med. 2017;34(7):887-901. https://doi.org/10.1111/dme.13324 PMid:28164387 DOI: https://doi.org/10.1111/dme.13324

Arceo ES, Dizon GA, Tiongco RE. Serum cystatin C as an early marker of nephropathy among Type 2 diabetics: A meta-analysis. Diabetes Metab Syndr. 2019;13(6):3093-7. https://doi.org/10.1016/j.dsx.2019.11.007 PMid:31778883 DOI: https://doi.org/10.1016/j.dsx.2019.11.007

Ebert N, Shlipak MG. Cystatin C is ready for clinical use. Curr Opin Nephrol Hyperten. 2020;29(6):591-8. https://doi.org/10.1097/MNH.0000000000000638 PMid:32868529 DOI: https://doi.org/10.1097/MNH.0000000000000638

Gupta K, Nayyar SB, Sachdeva J, Kumar P. Cystatin C in the early diagnosis of diabetic nephropathy and its correlation with albuminuria. Int J Adv Med. 2017;4(1):56-9. https://doi.org/10.18203/2349-3933.ijam20170020 DOI: https://doi.org/10.18203/2349-3933.ijam20170020

Fatrinawati W, Sianipar O. Accuracy of albumin creatinine ratio in comparison with albumine excretion rate for diagnosis diabetic nephropathy in Type 2 diabetes mellitus. J Med Sci. 2018;50(3):303-12. https://doi.org/10.19106/JMedScie/005003201806 DOI: https://doi.org/10.19106/JMedScie/005003201806

Mcgrath K, Edi R. Diabetic kidney disease: Diagnosis, treatment, and prevention. Am Fam Phys. 2019;99(12):751-9.

Al-Hazmi SF, Gad HG, Alamoudi AA, Eldakhakhny BM, Binmahfooz SK, Alhozali AM. Evaluation of early biomarkers of renal dysfunction in diabetic patients. Saudi Med J. 2020;41(7):690. https://doi.org/10.15537/smj.2020.7.25168 PMid:32601635 DOI: https://doi.org/10.15537/smj.2020.7.25168